SequelSEC

OPKO HEALTH, INC. OPK

Pharmaceutical Preparations · CIK 0000944809 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$587.90M
Fiscal year ended 2026-06-30
Operating income
-$48.25M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

OPKO HEALTH, INC. (OPK) reported revenue of $587.90M and net income of -$72.89M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from OPKO HEALTH, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

OPKO HEALTH, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$587.90M
Cost of revenue$348.20M
Gross profit$239.69M
Operating income-$48.25M
Net income-$72.89M
Research & development$125.22M
Weighted-average diluted sharesUnavailable
Pretax income-$79.82M
Income tax expense-$6.96M
Diluted EPS$-0.09
Selling, general & administrative$205.85M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

OPKO HEALTH, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$300.76M
Total assets$1.83B
Current assets$500.24M
Total liabilities$645.29M
Current liabilities$149.37M
Total equity incl. NCI$1.18B
Temporary (mezzanine) equityUnavailable
Inventory$61.85M
Accounts receivable$81.89M
Goodwill$481.52M
Long-term debt$1.78M
Accounts payable$50.04M

Cash flow

OPKO HEALTH, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$123.38M
Capital expendituresUnavailable
Investing cash flow$206.34M
Financing cash flow-$52.73M
Net change in cash$29.04M
Stock-based compensation$10.85M
Common dividends paidUnavailable
Common share repurchases$46.57M
Depreciation & amortization$89.72M

Derived

OPKO HEALTH, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin40.8%
Operating margin-8.2%
FCF marginUnavailable
SBC / revenue1.8%
Current ratio3.35x
Revenue YoY growth-11.5%
Net margin-12.4%
R&D / revenue21.3%
CapEx / revenueUnavailable
Long-term debt / equity0.00x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OPK in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q/A · Filed 2026-08-28View SEC filing
10-Q/A · Filed 2026-08-28View SEC filing
10-Q · Filed 2026-07-27View SEC filing
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-29View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.